Skip to main content

SBRT + atezolizumab and bevacizumab

SBRT With Atezo/Bev for HCC

  • RegistryNCT05488522
  • PhasePhase 1
  • StatusRecruiting
  • ConditionUnresectable Hepatocellular Carcinoma
  • SponsorAbramson Cancer Center at Penn Medicine
How SBRT + atezolizumab and bevacizumab worksNCT054885221 min

What the film says

Read the transcript

This trial is for advanced hepatocellular carcinoma, a liver cancer, that cannot be treated with curative surgery or ablation and needs systemic therapy, in adults.

The idea: repeat radiation alongside immunotherapy. Stereotactic body radiotherapy is given in repeated doses together with atezolizumab and bevacizumab. Both drugs are FDA approved for advanced liver cancer in combination.

This phase 1 study raises the radiation dose in steps to find a safe dose, and plans 18 patients. At the Abramson Cancer Center at Penn Medicine in Philadelphia, Edgar Ben-Josef leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05488522

    Advanced HCC not amenable to curative surgery or ablation, needing systemic therapy, adults; Repeated radiation doses with atezolizumab and bevacizumab; Dose raised in steps; safe dose; 18 patients; Abramson Cancer Center at Penn Medicine, Philadelphia; Edgar Ben-Josef (+1 more lines)

The drug

What is being tested.

Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT. Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC.

The study

How the trial runs.

A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.